S&P 500 falls as traders turn sour on tech
Investing.com - Canaccord Genuity raised its price target on Edwards Lifesciences (NYSE:EW) to $84.00 from $81.00 on Monday while maintaining a Hold rating, following the company’s strong third-quarter performance. The new target aligns closely with InvestingPro’s Fair Value assessment, suggesting the stock is currently fairly valued with shares trading at $82.45, just 5% below its 52-week high of $87.09.
Edwards Lifesciences reported quarterly sales of $1,553 million, representing 12.6% year-over-year adjusted growth, exceeding both Canaccord’s estimate of $1,489 million and consensus expectations of $1,498 million. The company delivered adjusted earnings per share of $0.67, surpassing Canaccord’s $0.58 estimate and the consensus of $0.60. This performance contributes to the company’s impressive $5.88 billion in trailing twelve-month revenue and $2.29 in diluted EPS.
The quarterly strength was primarily driven by better-than-expected performance in Transcatheter Aortic Valve Replacement (TAVR), which grew 10.6% year-over-year at constant currency. The company attributed this growth to increased awareness of aortic stenosis, supported by clinical data and presentations from its asymptomatic work. InvestingPro data shows that 10 analysts have revised their earnings upwards for the upcoming period, reflecting growing confidence in Edwards’ business momentum.
Canaccord noted that Edwards Lifesciences is positioning itself well ahead of its December analyst day, citing continued uptake of PASCAL and EVOQUE in Transcatheter Mitral and Tricuspid Technologies (TMTT), a likely upcoming approval in Transcatheter Mitral Valve Replacement (TMVR), and renewed traction in TAVR.
The research firm also highlighted that Edwards Lifesciences’ bottom line is growing faster than its top line, with the company projecting 10% topline growth for next year, while noting that CFO Scott Ullem will step down in mid-2026 after 12 years with the company. Edwards maintains a strong financial position with a 78.19% gross profit margin and operates with moderate debt levels. For investors seeking deeper insights, InvestingPro offers a comprehensive Pro Research Report on Edwards Lifesciences, one of 1,400+ US equities covered with detailed analysis and actionable intelligence.
In other recent news, Edwards Lifesciences reported impressive financial results for the third quarter of 2025. The company exceeded Wall Street expectations with an adjusted earnings per share (EPS) of $0.67, surpassing the forecasted $0.59. Revenue also outperformed projections, reaching $1.55 billion compared to the anticipated $1.5 billion. In addition to their earnings success, Edwards Lifesciences received an upgrade from Raymond James. The firm elevated the company’s stock rating from Market Perform to Outperform, setting a price target of $96.00. Raymond James cited "fewer reasons to be neutral" on the company as a basis for the upgrade. These developments reflect positively on the company’s current performance and future outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.